Skip to main content

Table 3 Immune cell number and phenotype by CKD stage in age and sex-adjusted regression models

From: Emergence of T cell immunosenescence in diabetic chronic kidney disease

 

Stage 3 CKD

versus

eGFR ≥60

Stage 4/5 CKD

versus

eGFR ≥60

p for trend

 

ß

p value

ß

p value

Number CD3+

−18.09

0.68

− 163.13

0.021*

0.053

Number CD4+

−20.49

0.46

−110.87

0.013*

0.024*

Number CD8+

21.21

0.21

−37.09

0.17

0.73

CD4+ TNAIVE (%)

1.75

0.29

2.19

0.41

0.23

CD4+ TEFF (%)

−0.31

0.33

1.09

0.032*

0.29

CD4+ CD127+ (%)

−0.72

0.19

−3.21

< 0.001*

0.001*

CD4+ CD28- (%)

0.7

0.33

1.1

0.33

0.21

CD4+ CD57+ (%)

0.32

0.47

0.32

0.65

0.46

CD8+ TNAIVE (%)

−2.59

0.045*

−3.24

0.12

0.024*

CD8+ TEFF (%)

4.96

0.015*

4.9

0.14

0.015*

CD8+ CD127+ (%)

−4.66

0.009*

−3.59

0.21

0.019*

CD8+ CD28- (%)

6.04

0.002*

5.14

0.1

0.004*

CD8+ CD57+ (%)

3.45

0.041*

4.6

0.089

0.018*

Number CD68+

23.5

0.16

0.43

0.99

0.45

Monocyte 1 (%)

0.54

0.55

2.17

0.13

0.15

Monocyte 2 (%)

−0.19

0.29

−0.25

0.38

0.22

Monocyte 3 (%)

−0.78

0.13

−1.24

0.13

0.053

  1. Age and sex-adjusted multivariable regression models and trend analyses to test the independent associations between immune profile and CKD stages. *: P value < 0.05. eGFR, estimated glomerular filtration rate derived from the CKD-EPI formula. Stage 3 CKD, eGFR between 30 and 60; stage 4 CKD, eGFR between 15 and 30; stage 5 CKD, eGFR less than 15. Monocyte 1: classical monocytes. Monocyte 2: intermediate monocytes. Monocyte 3: non-classical monocyte